[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100520846":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":45,"collaborators":19,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":49,"sex":55,"minAge":56,"maxAge":19,"enrollmentInfo":57,"targetDuration":19,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Jules Bordet Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"FAPI PET\u002FCT","EXPERIMENTAL","Patients with known or suspected peritoneal metastases from colorectal and ovarian cancers scheduled for complete cytoreductive surgery undergo FAPI PET\u002FCT before the planned surgery.\n\nIn the target population, patients receiving neoadjuvant chemotherapy undergo FAPI PET\u002FCT both before and after chemotherapy.",[13],"Diagnostic Test: FAPI PET\u002FCT",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DIAGNOSTIC_TEST","The radiopharmaceutical 68Gallium-FAPI-46 (FAPI) is applied intravenously for molecular imaging of FAP expression with FAPI PET\u002FCT.",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Patrick Flamen","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Loubna Taraji Schiltz","CONTACT","+32 (0) 2 541 37 81","loubna.taraji@hubruxelles.be",[31],{"facility":32,"status":33,"city":34,"state":19,"zip":19,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Institut Jules Bordet","RECRUITING","Brussels","Belgium","BE",{"type":38,"coordinates":39},"Point",[40,41],4.34878,50.85045,{"lat":41,"lon":40},[44],{"name":26,"role":27,"phone":19,"phoneExt":19,"email":29},{"type":46,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100520846","ga68-fapi-46-petct-for-preoperative-assessment-of-peritoneal-carcinomatosis-100520846",false,"NCT06061874","Ga68-FAPI-46 PET\u002FCT for Preoperative Assessment of Peritoneal Carcinomatosis","Ga68-labeled Fibroblast Activation Protein Inhibitor-46 (Ga68-FAPI-46) PET\u002FCT for Preoperative Assessment of Peritoneal Carcinomatosis","FAPeCa","Inclusion Criteria:\n\n* Histologically proven colorectal and ovarian cancer.\n* Known or suspected peritoneal metastases from the tumour of origin.\n* Scheduled for peritoneal complete cytoreductive surgery with curative intent with or without neoadjuvant chemotherapy.\n* ECOG (Eastern Cooperative Oncology Group) Performance status ≤2.\n* Signed written informed consent obtained before any study-specific screening procedures.\n\nExclusion Criteria:\n\n* Non-resectable extra-abdominal metastasis and\u002For \\>3 hepatic metastases on standard work-up\n* Known chronic inflammatory conditions including the intestinal system (eg. inflammatory bowel disease, Crohn's disease)\n* Pregnant and lactating women\n* Previous or concurrent malignancy diagnosed within the last 3 years except adequately treated in situ carcinoma of the cervix uteri and basal or squamous cell skin cancer.\n* Subjects with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study.","ALL","18 Years",{"count":58,"type":59},80,"ESTIMATED","INTERVENTIONAL",[62],"NA","This is a prospective, phase II, non-randomized clinical imaging trial. Ga68-FAPI-46 is a novel radiotracer used in PET\u002FCT imaging, targeting a protein of the tumor microenvironment called FAP (Fibroblast activation protein).\n\nThe aim of the study is to assess the accuracy of Ga68-FAPI-46 PET\u002FCT for preoperative assessment of peritoneal carcinomatosis in colorectal and ovarian cancer.",[65,66],"Cancer","Peritoneal Carcinomatosis",[68,69,70,71,72,73,74,75,76,77],"colorectal cancer","ovarian cancer","peritoneal carcinomatosis","fibroblast activation protein inhibitor","positron emission tomography","FAPI-46","PET","FAPI","PET\u002FCT","fibroblast activation protein","2025-03-26",{"date":80,"type":81},"2025-03-31","ACTUAL",{"date":83,"type":81},"2023-05-30",{"date":85,"type":59},"2025-12",{"name":5,"class":6},1]